MRNA
Moderna Inc
Moderna Inc historical holders
total: 5
H&H International Investment Moderna Inc transactions over time
- Total transactions:
- 11
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 5
- Held since:
- 2021 Q4
- Held for:
- 14 quarters
- Latest activity:
- 2025 Q2
Duan Yongping has been an institutional investor in Moderna Inc (MRNA) since 2021 Q4. According to 2026 Q1 report, Duan Yongping doesn't hold any shares. The fund/company first acquired MRNA in 2021 Q4, initially purchasing 60,000 shares. Since the initial investment, H&H International Investment has made 10 more transactions in this position.
When did Duan Yongping exit their MRNA position?
Duan Yongping no longer holds Moderna Inc (MRNA). They sold off their entire position in 2025 Q2, closing out an investment that began in 2021 Q4.
When did Duan Yongping first invest in MRNA?
Duan Yongping first invested in Moderna Inc (MRNA) in 2021 Q4 at the reported quarter-end price of $253.98 per share, acquiring 60,000 shares in their initial purchase.
What is Duan Yongping's average cost basis for MRNA?
Based on historical transaction data, Duan Yongping's estimated cost basis for Moderna Inc (MRNA) is approximately $148.21 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $148.21
- Weighted AVG sell price:
- $53.30
MRNA transactions history by H&H International Investment
11 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.00%
|
0
|
$28.35
|
|
-100% (-83,000)
|
-0.02%
|
|
2025 Q1
|
0.02%
|
83,000
|
$28.35
|
$2,353,050
|
-49.08% (-80,000)
|
-0.02%
|
|
2024 Q4
|
0.05%
|
163,000
|
$41.58
|
$6,777,540
|
+66.84% (+65,300)
|
+0.02%
|
|
2024 Q3
|
0.04%
|
97,700
|
$66.83
|
$6,529,291
|
-30.56% (-43,000)
|
-0.02%
|
|
2024 Q1
|
0.11%
|
140,700
|
$106.56
|
$14,992,992
|
+0.14% (+200)
|
+0%
|
|
2023 Q4
|
0.10%
|
140,500
|
$99.45
|
$13,972,725
|
+35.10% (+36,500)
|
+0.03%
|
|
2023 Q3
|
0.08%
|
104,000
|
$103.29
|
$10,742,160
|
-25.71% (-36,000)
|
-0.03%
|
|
2023 Q2
|
0.12%
|
140,000
|
$121.50
|
$17,010,000
|
-6.67% (-10,000)
|
-0.01%
|
|
2023 Q1
|
0.17%
|
150,000
|
$153.58
|
$23,037,000
|
-6.25% (-10,000)
|
-0.01%
|
|
2022 Q1
|
0.29%
|
160,000
|
$172.26
|
$27,562,000
|
+166.67% (+100,000)
|
+0.18%
|
|
2021 Q4
|
0.19%
|
$253.98
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.